Literature DB >> 15990011

Salvage surgery after failure of very accelerated radiotherapy in advanced head-and-neck squamous cell carcinoma.

Stephane Temam1, Erwin Pape, François Janot, Pierre Wibault, Morbize Julieron, Antoine Lusinchi, Gérard Mamelle, Patrick Marandas, Bernard Luboinski, Jean Bourhis.   

Abstract

PURPOSE: To assess the efficacy and toxicity of salvage surgery for local or cervical nodal recurrence after accelerated radiotherapy for locally advanced head-and-neck squamous cell carcinoma (HNSCC). METHODS AND MATERIALS: We reviewed the medical records of the 136 patients with HNSCC who had been treated in three consecutive clinical trials at the Institut Gustave-Roussy using a very accelerated radiotherapy regimen (62 to 64 Gy with 2 daily fractions of 1.8 to 2 Gy over 3.5 weeks). Sixty-nine patients of the 136 initial patients (51%) had local or neck lymph nodes relapse, or both.
RESULTS: Sixteen of these 69 patients (23%) had undergone salvage surgery for recurrence locally (n = 8) or in the cervical nodes (n = 8). All 16 had initially been diagnosed with locally advanced oropharyngeal carcinoma (T4, 11 patients; T3, 5 patients), and 13 had initially had cervical node involvement. After salvage surgery, 6 patients had had a local recurrence; 7, cervical node recurrence; and 3, distant metastasis. Thus, salvage surgery had been successful only in 3 patients. The 3- and 5-year overall actuarial survival rates were 20% and 11%, respectively. Eight patients had major postoperative wound complications, including carotid rupture in three cases.
CONCLUSION: Salvage surgery for relapse after very accelerated radiotherapy for advanced HNSCC is infrequently feasible and is of limited survival benefit. It should be used only in carefully selected cases.

Entities:  

Mesh:

Year:  2005        PMID: 15990011     DOI: 10.1016/j.ijrobp.2004.12.062

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  18 in total

1.  Hyperfractionated stereotactic reirradiation for recurrent head and neck cancer.

Authors:  Jakub Cvek; Lukas Knybel; Eva Skacelikova; Jiri Stransky; Petr Matousek; Karol Zelenik; Oldrich Res; Bretislav Otahal; Lukas Molenda; David Feltl
Journal:  Strahlenther Onkol       Date:  2015-08-28       Impact factor: 3.621

2.  Reirradiation for recurrent head and neck cancers using charged particle or photon radiotherapy.

Authors:  Hideya Yamazaki; Yusuke Demizu; Tomoaki Okimoto; Mikio Ogita; Kengo Himei; Satoaki Nakamura; Gen Suzuki; Ken Yoshida; Tadayuki Kotsuma; Yasuo Yoshioka; Ryoongjin Oh
Journal:  Strahlenther Onkol       Date:  2017-04-19       Impact factor: 3.621

3.  Outcome after re-irradiation of head and neck cancer patients.

Authors:  Nele Platteaux; Piet Dirix; Bianca Vanstraelen; Sandra Nuyts
Journal:  Strahlenther Onkol       Date:  2010-12-22       Impact factor: 3.621

4.  Management of recurrent head and neck cancer: variables related to salvage surgery.

Authors:  Laura Gañán; Montserrat López; Jacinto García; Eduard Esteller; Miquel Quer; Xavier León
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-05-17       Impact factor: 2.503

5.  A retrospective, deformable registration analysis of the impact of PET-CT planning on patterns of failure in stereotactic body radiation therapy for recurrent head and neck cancer.

Authors:  Kyle Wang; Dwight E Heron; John C Flickinger; Jean-Claude M Rwigema; Robert L Ferris; Gregory J Kubicek; James P Ohr; Annette E Quinn; Cihat Ozhasoglu; Barton F Branstetter
Journal:  Head Neck Oncol       Date:  2012-04-19

6.  Assessment of peri- and postoperative complications and Karnofsky-performance status in head and neck cancer patients after radiation or chemoradiation that underwent surgery with regional or free-flap reconstruction for salvage, palliation, or to improve function.

Authors:  Christian Simon; Cem Bulut; Philippe A Federspil; Marc W Münter; Katja Lindel; Zazie Bergmann; Serkan Sertel; Sarah Leitzbach; Peter K Plinkert
Journal:  Radiat Oncol       Date:  2011-09-06       Impact factor: 3.481

Review 7.  Reirradiation of head and neck cancer focusing on hypofractionated stereotactic body radiation therapy.

Authors:  Hideya Yamazaki; Naohiro Kodani; Mikio Ogita; Kengo Sato; Kengo Himei
Journal:  Radiat Oncol       Date:  2011-08-21       Impact factor: 3.481

8.  Predictive value of skin invasion in recurrent head and neck cancer patients treated by hypofractionated stereotactic re-irradiation using a cyberknife.

Authors:  Hideya Yamazaki; Mikio Ogita; Kengo Himei; Satoaki Nakamura; Gen Suzuki; Tadayuki Kotsuma; Ken Yoshida; Yasuo Yoshioka
Journal:  Radiat Oncol       Date:  2015-10-15       Impact factor: 3.481

9.  Reirradiation using robotic image-guided stereotactic radiotherapy of recurrent head and neck cancer.

Authors:  Hideya Yamazaki; Mikio Ogita; Kengo Himei; Satoaki Nakamura; Gen Suzuki; Ken Yoshida; Tadayuki Kotsuma; Yasuo Yoshioka
Journal:  J Radiat Res       Date:  2016-03-16       Impact factor: 2.724

10.  Reirradiation of recurrent head and neck cancer using high-dose-rate brachytherapy.

Authors:  V Rudzianskas; A Inciura; E Juozaityte; M Rudzianskiene; R Kubilius; S Vaitkus; M Kaseta; D Adliene
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-10       Impact factor: 2.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.